+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antibiotic Renaissance: Technology and Market Advances in the War against Drug-resistant Bacteria

  • ID: 3067967
  • Report
  • June 2014
  • Region: Global
  • 111 Pages
  • Insight Pharma Reports
1 of 3

FEATURED COMPANIES

  • Accelerate Diagnostics
  • Atlas Genetics
  • Cepheid
  • Enanta Pharmaceuticals
  • Merck
  • Phico Therapeutics
  • MORE
This report covers evolutionary growth of antibiotic resistant bacteria with a focus in research aspects, commercial aspects, market aspects, and trends in antibiotic resistance. Antibiotic resistance has a historical presence in the big pharma industry (documentation of its understanding leads back to 1940); however it has only recently been on the incline of popular adoption. Because of the rapid development of antibiotics and the growing pharma industry, most professionals felt secure in the belief that for every antibiotic fallen by the wayside, new ones would emerge to replace them, much to the chagrin of the smaller population of physicians and medical scientists. Due to technical difficulty, regulatory complexity, and relatively poor returns on investment, commercial drug developers became progressively less enamored with nurturing the antibiotic industry. One by one, big pharmas dropped out of the bacterial infectious disease space in favor of therapeutic areas offering greater blockbuster potential.

Although researchers have reached a point to develop antibiotics to drug-resistant bacteria, the morbidity and mortality from drug-resistant infections have resultantly scourged a variety of regions and industries, including our most useful medical facilities. In an effort to raise awareness and take action, governments, professional societies, and a growing body of medical researchers have published papers and reports that highlight the problems, call for remedial action, and propose action plans. Accordingly, academic, governmental, and commercial players have begun to ramp up activities in response to these calls to arms.

Highlighted in this report are the following concepts:

- History, status, and progress of drug resistant bacteria
- Evolution of today’s antibiotic resistant bacteria
- Diagnostic and therapeutic research programs directed at alleviating medical problems caused by antibiotic resistant bacteria
- Survey results exploiting commercial diagnostic and therapeutic programs and market-related aspects of antibiotic resistance
- Trends developing in the field
- Exclusive interviews with six individuals who are highly knowledgeable in the subject area
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Accelerate Diagnostics
  • Atlas Genetics
  • Cepheid
  • Enanta Pharmaceuticals
  • Merck
  • Phico Therapeutics
  • MORE
Executive Summary
Research Aspects Of Antibiotic Resistance
Commercial Aspects Of Antibiotic Resistance
Market Aspects
Trends In Antibiotic Resistance

Chapter 1: Introduction
Scope And Contents

Chapter 2: History And Background
Antibiotics And The Pharmaceutical Industry
Diagnostics Background

Chapter 3: Research Aspects Of Antibiotic Resistance
Diagnostics
Ge Global Research/University Of Washington/Epoch Biosciences
Massachusetts General Hospital
Pak Kin Wong Lab, University Of Arizona
Q-Linea Ab
University Of Tokyo/Osaka University
University Hospital, Basel, Switzerland
University Of Illinois
University Of Toronto/Xagenic
Brown University/Mit
David Greenberg Laboratory, University Of Texas
Discuva
Eric Brown Lab, Mcmaster University
Ibm/Institute Of Bioengineering And Nanotechnology (Singapore)
Kenneth Keiler Laboratory, Pennsylvania State University
Kim Lewis Lab, Northeastern University
Michael Laub Laboratory, Massachusetts Institute Of Technology
Netherlands Cancer Center/Universitat Pompeu Fabra/Hubrecht Institute
Novobiotic
Udi Qimron Laboratory, Tel Aviv University
University Of Illinois/University Of California, San Diego
University Of Southern Denmark
Washington University School Of Medicine

Chapter 4: Commercial Aspects Of Antibiotic Resistance
Diagnostic Products And Projects
Molecular Diagnostic Approaches
Alere
Atlas Genetics
Bd Diagnostics
Biofire
Cepheid
Curetis
Diatherix
Elitech Molecular Diagnostics
Great Basin Corporation
Mobidiag
Molecular Detection Inc.
Q-Linea Ab
Roche Molecular Systems
Stat-Diagnostica
Culture-Based Approaches
Accelerate Diagnostics
Axela Inc. And Hutman Diagnostics
Mass Spectrometry-Based Diagnostics
Therapeutic Products And Projects
Achaogen
Achillion Pharmaceuticals
Affinium Pharmaceuticals
Allecra Therapeutics
Astrazeneca
Basilea Pharmaceutical
Biota Pharmaceuticals
Cellceutix
Cempra Pharmaceuticals
Contrafect
Cubist Pharmaceuticals
Durata Therapeutics
Enanta Pharmaceuticals
Forest Laboratories
Glaxosmithkline
Helperby Therapeutics
Johnson & Johnson
Melinta Therapeutics
Merck
Nabriva Therapeutics
Novolytics
Paratek Pharmaceuticals
Pfizer
Phico Therapeutics
Polyphor Ltd.
Shionogi And Co., Ltd.
Taigen Biotechnology
Tetraphase Pharmaceuticals
The Medicines Company

Chapter 5: Market Aspects Of Antibiotic Resistance
Deals
Survey Results

Chapter 6: Trends In Antibiotic Resistance
Consortia, Regulatory Initiatives, And Collaborative Programs
Difficulties For Infectious Disease Drug Discoverers And Developers
New Approaches To Discovering Drugs To Avoid Antibiotic Resistance

Chapter 7: Interview Transcripts
Glenn Tillotson, Phd, Senior Partner, Transcrip Partners, Usa
David Shlaes, Md, Phd
Kim Lewis, Ph.D.
Lawrence Mehren
Stuart B. Levy, M.D.
Shana Kelley, Ph.D.
Note: Product cover images may vary from those shown
3 of 3
- Alere
- Atlas Genetics
- Bd Diagnostics
- Biofire
- Cepheid
- Curetis
- Diatherix
- Elitech Molecular Diagnostics
- Great Basin Corporation
- Mobidiag
- Molecular Detection Inc.
- Q-Linea Ab
- Roche Molecular Systems
- Stat-Diagnostica
- Culture-Based Approaches
- Accelerate Diagnostics
- Axela Inc. And Hutman Diagnostics
- Mass Spectrometry-Based Diagnostics
- Therapeutic Products And Projects
- Achaogen
- Achillion Pharmaceuticals
- Affinium Pharmaceuticals
- Allecra Therapeutics
- Astrazeneca
- Basilea Pharmaceutical
- Biota Pharmaceuticals
- Cellceutix
- Cempra Pharmaceuticals
- Contrafect
- Cubist Pharmaceuticals
- Durata Therapeutics
- Enanta Pharmaceuticals
- Forest Laboratories
- Glaxosmithkline
- Helperby Therapeutics
- Johnson & Johnson
- Melinta Therapeutics
- Merck
- Nabriva Therapeutics
- Novolytics
- Paratek Pharmaceuticals
- Pfizer
- Phico Therapeutics
- Polyphor Ltd.
- Shionogi And Co., Ltd.
- Taigen Biotechnology
- Tetraphase Pharmaceuticals
- The Medicines Company
Note: Product cover images may vary from those shown
Adroll
adroll